Get the Stockscreener App
102.88
5.01%
-5.43
After Hours:
102.88
Neurocrine Biosciences Inc stock is traded at $102.88, with a volume of 1.76M.
It is down -5.01% in the last 24 hours and down -10.13% over the past month.
See More
Previous Close:
$108.31
Open:
$105.32
24h Volume:
1.76M
Relative Volume:
1.42
Market Cap:
$10.60B
Revenue:
$2.24B
Net Income/Loss:
$385.90M
P/E Ratio:
27.58
EPS:
3.73
Net Cash Flow:
$440.10M
1W Performance:
-9.75%
1M Performance:
-10.13%
6M Performance:
-8.04%
1Y Performance:
-25.23%
1-Day Range:
$102.55
$107.53
1-Week Range:
$102.55
$114.42
52-Week Range:
$102.55
$157.98
Neurocrine Biosciences Inc Stock (NBIX) Company Profile
Name
Neurocrine Biosciences Inc
Sector
Phone
(858) 617-7600
Address
6027 EDGEWOOD BEND COURT, SAN DIEGO, CA
Compare NBIX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NBIX
Neurocrine Biosciences Inc
|
102.88 | 10.60B | 2.24B | 385.90M | 440.10M | 3.73 |
|
ZTS
Zoetis Inc
|
159.61 | 73.88B | 9.26B | 2.49B | 2.30B | 5.47 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.19 | 48.17B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
HLN
Haleon Plc Adr
|
10.45 | 47.59B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
14.85 | 17.28B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
307.36 | 13.78B | 2.76B | 1.11B | 898.10M | 22.77 |
Neurocrine Biosciences Inc Stock (NBIX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-11-25 | Initiated | Deutsche Bank | Hold |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Aug-29-24 | Upgrade | Piper Sandler | Neutral → Overweight |
| Apr-24-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Dec-13-23 | Resumed | Citigroup | Neutral |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Oct-24-23 | Resumed | Cantor Fitzgerald | Overweight |
| Aug-21-23 | Reiterated | Mizuho | Neutral |
| Jul-24-23 | Upgrade | SVB Securities | Market Perform → Outperform |
| Jul-06-23 | Upgrade | BMO Capital Markets | Underperform → Market Perform |
| May-04-23 | Upgrade | Guggenheim | Neutral → Buy |
| Mar-30-23 | Upgrade | Canaccord Genuity | Hold → Buy |
| Mar-03-23 | Upgrade | Evercore ISI | In-line → Outperform |
| Feb-03-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-14-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Oct-11-22 | Initiated | UBS | Buy |
| Sep-26-22 | Initiated | Wells Fargo | Equal Weight |
| Jun-06-22 | Resumed | Jefferies | Buy |
| Mar-03-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Feb-25-22 | Upgrade | Goldman | Neutral → Buy |
| Jan-18-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-19-21 | Initiated | BMO Capital Markets | Underperform |
| Nov-17-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-14-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-23-21 | Resumed | Needham | Hold |
| Aug-06-21 | Downgrade | Canaccord Genuity | Buy → Hold |
| May-18-21 | Resumed | Goldman | Neutral |
| May-06-21 | Upgrade | Barclays | Equal Weight → Overweight |
| Feb-02-21 | Initiated | Raymond James | Outperform |
| Sep-30-20 | Initiated | The Benchmark Company | Hold |
| Aug-04-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Jun-29-20 | Downgrade | Goldman | Buy → Neutral |
| Jun-09-20 | Initiated | Wedbush | Outperform |
| Mar-06-20 | Initiated | Citigroup | Buy |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Feb-24-20 | Initiated | William Blair | Outperform |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Feb-05-20 | Reiterated | H.C. Wainwright | Buy |
| Dec-13-19 | Downgrade | Credit Suisse | Outperform → Neutral |
| Aug-07-19 | Initiated | RBC Capital Mkts | Outperform |
| Jul-16-19 | Initiated | Oppenheimer | Outperform |
| Jun-05-19 | Initiated | Guggenheim | Neutral |
| May-21-19 | Initiated | Credit Suisse | Outperform |
| Apr-22-19 | Upgrade | JP Morgan | Neutral → Overweight |
| Apr-12-19 | Initiated | Evercore ISI | Outperform |
| Feb-06-19 | Reiterated | BofA/Merrill | Buy |
| Jan-23-19 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-13-18 | Initiated | Goldman | Buy |
| Nov-21-18 | Initiated | Canaccord Genuity | Buy |
View All
Neurocrine Biosciences Inc Stock (NBIX) Latest News
Neurocrine Biosci stock hits 52-week low at $105.17 - Investing.com
Cerebral Palsy Market Growth Projections 2024-2034: DelveInsight Analysis | Neurocrine Biosciences, Teva Pharma, Bundang CHA Hospital, Jazz Pharma - The Globe and Mail
Mitsubishi UFJ Trust & Banking Corp Sells 4,578 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
Neurocrine Biosciences executive sells shares worth $266,024 - MSN
New Data: INGREZZA Outperforms Competitors with Perfect Therapeutic Dose Rate - Stock Titan
Supporting a Loved One Living with a Mental Health Condition and Tardive Dyskinesia - Main Street Media of Tennessee
Neurocrine Biosciences: A Smart Biotech Bet With Blockbuster Potential - The Globe and Mail
Deep Dive Into Neurocrine Biosciences Stock: Analyst Perspectives (14 Ratings) - Benzinga
Ashland, Connectone Bancorp, Neurocrine Biosciences - TradingView
Tardive Dyskinesia Treatment Market Expands with New Drug - openPR
Neurocrine Biosciences debuts new data for effectiveness of Ingrezza - Yahoo Finance
Neurocrine touts further positive trial results for Ingrezza - The Pharma Letter
Neurocrine Biosciences (NBIX) Presents 48-Week Remission Data on Treatment of Tardive Dyskinesia With INGREZZA Capsules - StreetInsider.com
Neurocrine Biosciences Presents 48-Week Remission Data on Treatment of Tardive Dyskinesia With INGREZZA® (valbenazine) Capsules - PR Newswire
Breakthrough: INGREZZA Achieves 59% Remission in Tardive Dyskinesia Patients Over 48 Weeks - Stock Titan
Endometriosis Pain Pipeline 2025: FDA Approvals and Clinical - openPR
Neurocrine at Stifel 2025 CNS Forum: Strategic Insights and Challenges - Investing.com
Neurocrine Biosciences (NBIX): Among the Best Biotech Stocks to Buy According to Billionaires - Yahoo Finance
Is Neurocrine Biosciences, Inc. (NBIX) a Best Biotech Stock According to Billionaires? - Insider Monkey
Neurocrine Biosciences Presents New Data From KINECT-HD Study Of Ingrezza - Nasdaq
Breakthrough: INGREZZA Phase 3 Data Reveals Powerful Chorea Control Across All Body Regions - StockTitan
Neurocrine Biosciences chief legal officer sells $254,991 in stock - MSN
Neurocrine Biosciences (NASDAQ:NBIX) Stock Rating Upgraded by StockNews.com - Defense World
Schizophrenia Treatment Market Size Report 2034 | Novartis - openPR
US Bancorp DE Increases Stock Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - Defense World
RBC Capital cuts Neurocrine Bio. stock target to $139 from $148 - Investing.com India
Trend Tracker for (NBIX) - Stock Traders Daily
Voyager Reports Fourth Quarter and Full Year 2024 Financial and Operating Results - GlobeNewswire
Neurocrine Biosciences to Present at the Stifel 2025 Virtual CNS Forum - PR Newswire
RBC Cuts Price Target on Neurocrine Biosciences to $139 From $148, Keeps Sector Perform Rating - Marketscreener.com
Smartleaf Asset Management LLC Purchases 146 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - Defense World
Neurocrine Biosciences, Inc. to Host Earnings Call - ACCESS Newswire
Morgan Stanley Reiterates Overweight Rating for Neurocrine Biosciences (NASDAQ:NBIX) - Defense World
Positive Growth Outlook for Neurocrine Biosciences Driven by Ingrezza and Crenessity Sales Projections - TipRanks
Tardive Dyskinesia Treatment Market Size, Share & Future - openPR
Acetylcholine Receptor Antagonists Clinical Trial Pipeline Appears Robust With 30+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - GlobeNewswire Inc.
Neurocrine Biosciences (NasdaqGS:NBIX) Begins Phase 1 Study Of New VMAT2 Inhibitor For Neurological Conditions - Simply Wall St
Neurocrine Biosciences initiates trial of VMAT2 inhibitor in healthy adults - Yahoo Finance
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World
Neurocrine Biosciences Announces Initiation Of Phase 1 Clinical Study Evaluating NBI-1140675 - Marketscreener.com
Neurocrine begins phase 1 study of new neurological drug By Investing.com - Investing.com South Africa
Neurocrine begins phase 1 study of new neurological drug - Investing.com India
Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBI-1140675, a Second-Generation VMAT2 Inhibitor, in Healthy Adults - PR Newswire
Neurocrine Biosciences, Inc.'s (NASDAQ:NBIX) Stock Retreats 25% But Earnings Haven't Escaped The Attention Of Investors - Simply Wall St
Neurological Disorder Drugs Market Detailed In New Research - openPR
Neurocrine Biosci stock hits 52-week low at $110.92 - Investing.com
Why Neurocrine Biosciences Inc. (NBIX) Crashed Last Week - MSN
Fjarde AP Fonden Fourth Swedish National Pension Fund Has $7.59 Million Stock Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
Illumine Investment Management LLC Invests $1.30 Million in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
GW&K Investment Management LLC Grows Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
Los Angeles Capital Management LLC Has $70 Million Stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
Neurocrine Biosciences Inc Stock (NBIX) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.77%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):